Sopharma AD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sopharma AD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	13.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	24 Jan 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BUL:SFA - Analysts future estimates and past financials data (BGN Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	1,989	72	N/A	N/A	1
12/31/2023	1,888	95	2	45	N/A
9/30/2023	1,832	81	-30	3	N/A
6/30/2023	1,787	91	45	77	N/A
3/31/2023	1,742	83	81	107	N/A
12/31/2022	1,672	71	86	110	N/A
9/30/2022	1,651	107	8	31	N/A
6/30/2022	1,655	101	-25	-1	N/A
3/31/2022	1,629	92	-67	-42	N/A
12/31/2021	1,611	89	-103	-76	N/A
9/30/2021	1,608	58	-128	-109	N/A
6/30/2021	1,527	41	-143	-117	N/A
3/31/2021	1,460	37	-177	-153	N/A
12/31/2020	1,446	30	-206	-179	N/A
9/30/2020	1,375	75	-193	-155	N/A
6/30/2020	1,353	85	-198	-160	N/A
3/31/2020	1,340	82	-187	-145	N/A
12/31/2019	1,288	87	-168	-128	N/A
9/30/2019	1,257	35	-177	-141	N/A
6/30/2019	1,231	30	-158	-123	N/A
3/31/2019	1,209	31	-156	-127	N/A
12/31/2018	1,188	28	-152	-124	N/A
9/30/2018	1,166	34	-141	-111	N/A
6/30/2018	1,125	32	-111	-90	N/A
3/31/2018	1,077	35	-96	-73	N/A
12/31/2017	1,024	40	-81	-58	N/A
9/30/2017	965	52	N/A	-53	N/A
6/30/2017	930	53	N/A	-89	N/A
3/31/2017	906	57	N/A	-67	N/A
12/31/2016	883	51	N/A	-69	N/A
9/30/2016	874	29	N/A	-32	N/A
6/30/2016	867	21	N/A	22	N/A
3/31/2016	878	23	N/A	50	N/A
12/31/2015	883	21	N/A	67	N/A
9/30/2015	883	24	N/A	61	N/A
6/30/2015	877	29	N/A	50	N/A
3/31/2015	860	17	N/A	36	N/A
12/31/2014	852	20	N/A	38	N/A
9/30/2014	833	19	N/A	38	N/A
6/30/2014	811	19	N/A	41	N/A
3/31/2014	793	24	N/A	56	N/A
12/31/2013	767	29	N/A	53	N/A
9/30/2013	738	30	N/A	45	N/A
6/30/2013	717	39	N/A	22	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SFA's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if SFA's earnings are forecast to grow faster than the BG market

High Growth Earnings: Insufficient data to determine if SFA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SFA's revenue is forecast to grow faster than the BG market.

High Growth Revenue: Insufficient data to determine if SFA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SFA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sopharma AD Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Price target decreased to лв3.48

Price target decreased to лв3.48

Price target lowered to лв3.24

Recent updates

Now 23% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.4% yield

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

New minor risk - Share price stability

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

New minor risk - Shareholder dilution

Chairman recently bought лв72k worth of stock

Investor sentiment improves as stock rises 17%

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought лв81k worth of stock

Chairman recently sold лв1.1m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold лв297k worth of stock

New minor risk - Dividend sustainability

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Sopharma AD, Annual General Meeting, Jun 03, 2022

Less than half of directors are independent

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released

Chairman recently bought лв79k worth of stock

Price target decreased to лв3.48

Price target decreased to лв3.48

First quarter 2021 earnings released

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

New 90-day high: лв3.50

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

New 90-day high: лв3.26

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

New 90-day high: лв3.18

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

New 90-day high: лв3.16

Price target lowered to лв3.24

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity